What is the first line treatment for Guillain-Barré Syndrome (GBS)?

In the management of Guillain-Barré Syndrome (GBS), the primary treatments are plasmapheresis and intravenous immunoglobulin (IVIG). Both modalities are considered first-line therapies and are effective in alleviating symptoms and hastening recovery in GBS patients.

Plasmapheresis involves the removal of plasma from the blood, which can help eliminate antibodies that are attacking the peripheral nervous system. This process can reduce the severity and duration of the syndrome.

IVIG, on the other hand, provides a concentrated form of antibodies that can modulate the immune response and diminish the autoimmune attack on the nervous system.

Both treatments have been shown to be effective in clinical studies, and the choice between them may depend on the patient's condition, accessibility, and potential side effects. Research and clinical guidelines endorse the use of either treatment, which is why recognizing that both are first-line options in GBS provides a comprehensive approach to managing this condition.

High doses of steroids are not recommended for GBS because they have not shown efficacy in modifying the disease course and can potentially worsen the condition.